CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CG Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$59.96+0.11 (+0.18%)
Close on Oct 19, 2026
- Market cap
- $5.29B
- P/E (TTM)
- –
- Dividend yield
- –
CG Oncology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | CG Oncology | Industry median |
|---|---|---|
| Market Cap | $5.31B | $166.30M |
| Enterprise Value | $4.29B | $88.19M |
| PS Ratio | 853.38 | 3.65 |
| PB Ratio | 5.16 | 2.03 |
| P/TBV Ratio | 5.22 | 2.29 |
Enterprise value
| Measure | CG Oncology | Industry median |
|---|---|---|
| EV / Sales | 688.76 | 2.51 |
Income (trailing twelve months)
| Measure | CG Oncology | Industry median |
|---|---|---|
| Revenue | $6.23M | $58.34M |
| Operating Income | -$252.62M | -$21.40M |
| Net Income | -$224.38M | -$22.46M |
| EBITDA | -$249.66M | -$16.91M |
| EPS (Diluted) | -$2.70 | -$0.83 |
Margins
| Measure | CG Oncology | Industry median |
|---|---|---|
| Operating Margin | -4056.2% | -44.0% |
| Profit Margin | -3602.7% | -40.2% |
| EBITDA Margin | -4008.7% | -30.2% |
| FCF Margin | -2879.6% | -9.27% |
Returns
| Measure | CG Oncology | Industry median |
|---|---|---|
| Return on Equity (ROE) | -26.4% | -53.2% |
| Return on Assets (ROA) | -25.1% | -40.9% |
| Return on Invested Capital (ROIC) | -3036.2% | -32.4% |
| Return on Capital Employed (ROCE) | -24.3% | -38.1% |
Growth
| Measure | CG Oncology | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 1030.3% | 5.96% |
Balance sheet
| Measure | CG Oncology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.03B | $61.43M |
| Total Debt | $3.00M | $118.52M |
| Net Cash (Debt) | $1.03B | $15.35M |
| Net Cash Per Share | $11.57 | $0.66 |
| Equity (Book Value) | $1.03B | $49.09M |
| Book Value Per Share | $11.61 | $1.37 |
| Tangible Book Value | $1.02B | $23.52M |
| Working Capital | $1.00B | $76.81M |
Financial position
| Measure | CG Oncology | Industry median |
|---|---|---|
| Current Ratio | 22.22 | 3.34 |
| Quick Ratio | 21.78 | 2.44 |
| Debt / Equity | 0.00 | 0.52 |
Cash flow (trailing twelve months)
| Measure | CG Oncology | Industry median |
|---|---|---|
| Operating Cash Flow | -$178.47M | -$12.35M |
| Capital Expenditures | -$876.00K | -$1.08M |
| Free Cash Flow | -$179.34M | -$20.22M |
| FCF Per Share | -$2.02 | -$0.42 |
Efficiency
| Measure | CG Oncology | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.39 |
| Revenue Per Employee | $43.86K | $404.87K |
| Profits Per Employee | -$1.58M | -$703.34K |
| Employee Count | 142 | 74 |
Dividends and yields
| Measure | CG Oncology | Industry median |
|---|---|---|
| Earnings Yield | -4.22% | -23.3% |
| FCF Yield | -3.37% | -8.72% |
Shares
| Measure | CG Oncology | Industry median |
|---|---|---|
| Shares Outstanding | 88,640,400 | 58,127,000 |
| Shares Change (YoY) | 14.2% | 10.9% |
| Shares Change (QoQ) | 0.34% | 0.54% |
| Float | 73,333,600 | 49,136,700 |
| Shares Held by Insiders | 17.3% | 11.6% |
| Shares Held by Institutions | 105.8% | 59.4% |
Scores
| Measure | CG Oncology | Industry median |
|---|---|---|
| Altman Z-Score | 56.08 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from CG Oncology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.